Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.
1 report, 1 independent
Updated Aug 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
-
BioMarin Pharmaceutical
American company
Related events
- Barclays issued rating and price objective reports for Ubiquiti on August 1, 2026.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.
- Barclays provided investment ratings for RELX stock on September 6, 2026.
- Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.
- Barclays maintained Overweight rating and raised price target on August 29, 2025.
Coverage
Newest first; wire copies grouped- Insider MonkeyBarclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks according to Wall Street anal